{"entity":{"id":"tng456","kind":"drug","name":"TNG456","aka":[],"tldr":"TNG456 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for non-small-cell lung cancer and glioma & glioblastoma, aimed at PRMT5 (MTAP-deleted cancers).","summary":"TNG456 is a small-molecule drug developed by Tango Therapeutics. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: A selective PRMT5 inhibitor being developed for cancers with MTAP loss/deletion, including glioblastoma. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and glioma & glioblastoma. The largest, NCT06810544, plans to enrol 191 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TNG456","url":"https://clinicaltrials.gov/search?intr=TNG456"},{"label":"Sponsor pipeline page","url":"https://tangotx.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","glioblastoma"],"sections":[],"technologies":[],"targets":["prmt5-mtap"],"drugs":[],"companies":["tango-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06810544"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"A selective PRMT5 inhibitor being developed for cancers with MTAP loss/deletion, including glioblastoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tng456/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/"}],"company":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/"}],"trial":[{"id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","route":"/trials/nct06810544/"}]}}